ACS Medicinal Chemistry Letters
August 25, 2025
Ram W. Sabnis
This patent document describes new chemical compounds that act as agonists at the 5-HT2A serotonin receptor, classifying them as serotonergic psychedelic agents. It claims pharmaceutical compositions containing these compounds and their use in treating psychosis, mental illness, and other central nervous system disorders. The document also outlines processes for synthesizing these compounds. The claims are technical and legal in nature, asserting novel chemical entities and their potential therapeutic applications, but no experimental data, clinical results, or evidence of efficacy are provided in this text.
ACS Medicinal Chemistry Letters
August 15, 2025
Robert B. Kargbo
Certain novel compounds, including psilocybin, show promise for treating psychiatric conditions through unique pharmacological actions. By modifying their chemical structure, researchers can achieve functional selectivity at serotonin (5-HT) receptors, reducing hallucinogenic effects while maintaining therapeutic benefits. The work combines receptor-level and behavioral evidence to support these compounds as rational treatments for demoralization syndrome and depression-related disorders.
ACS Medicinal Chemistry Letters
June 12, 2025
Robert B. Kargbo
New non-hallucinogenic compounds based on substituted tryptamines show promise for treating metabolic and neuropsychiatric disorders by selectively targeting 5-HT2A/2C receptors. Two recent patent applications describe analogs that avoid psychedelic effects while offering optimized receptor selectivity, potential metabolic benefits, and the ability to promote neuroplasticity. These agents represent a novel chemical framework for multimodal treatment strategies in brain disorders and metabolic health.
ACS Medicinal Chemistry Letters
April 10, 2025
Robert B. Kargbo
Psilocybin reduces phantom and residual limb pain by a clinically meaningful amount. Adaptive sensory environments (ASEs) use biosensors to guide modulation of psychological states during psychoactive therapy. This Patent Highlight reviews pharmacological findings from a psilocybin trial and discusses future integration with ASE systems to improve precision and scalability of psychedelic-assisted interventions.
ACS Medicinal Chemistry Letters
April 10, 2025
Robert B. Kargbo
Advancements in psychedelic therapeutics, tryptamine derivatives, neuroplastic modulators, and AI-powered machine-learning platforms are opening new possibilities in precision medicine. These innovations target neurological and psychiatric disorders, chronic pain, and computational accessibility through receptor modulation, targeted delivery, and simplified AI integration. They promise transformative solutions for patient care and technological development.
ACS Medicinal Chemistry Letters
April 10, 2025
Robert B. Kargbo
Psychedelics and artificial intelligence both alter cognitive frameworks, disrupt rigid thinking, and boost neuroplasticity, which may help treat depression, PTSD, and addiction. By relaxing neural filters, they induce altered states of consciousness that challenge how reality is perceived. This viewpoint examines the neurobiological mechanisms behind these effects and considers how AI could enhance psychiatric treatments.
ACS Medicinal Chemistry Letters
February 13, 2025
Robert B. Kargbo
Combining monoamine antidepressants with short-duration psychedelics like DMT and psilocybin, alongside AI-driven behavioral tracking, may offer rapid and sustained improvements for treatment-resistant depression and anxiety. AI-enhanced monitoring uses motion tracking and machine learning to quantify outcomes in animal models, speeding drug development. These approaches aim to personalize psychiatric care.
ACS Medicinal Chemistry Letters
December 12, 2024
Robert B. Kargbo
Psychedelic compounds like psilocybin and psilocin show therapeutic promise for neurological and psychiatric disorders, but their clinical use is limited by poor bioavailability, rapid metabolism, and stability issues. This Patent Highlight reviews recent innovations in drug delivery systems and psilocin analogs, including controlled-release systems, ester analogs, and acetal/ketal derivatives. These patents present novel approaches to improving stability, bioavailability, and efficacy, potentially leading to more effective treatments for depression, chronic pain, and neurodegenerative diseases.
ACS Medicinal Chemistry Letters
August 21, 2024
Robert B. Kargbo
A review of three patent applications examines the potential of entheogens such as psilocybin to treat cognitive decline and bolster psychological resilience in patients receiving anesthesia or sedation. The article describes proposed therapeutic mechanisms, treatment methods, and possible clinical outcomes for postoperative care. It provides an overview of this emerging approach without presenting original data or empirical findings.
ACS Medicinal Chemistry Letters
August 21, 2024
Robert B. Kargbo
Recent psychedelic research has produced lysergic acid derivatives with modified LSD-like effects, a psilocybin dosing method guided by ABCF1 gene expression, and new treatments for binge eating disorder. Neuroenhancement techniques that boost emotional responses are also being explored. These developments point toward personalized medicine and expanded mental health applications, signaling a transformative phase in clinical psychedelic use.
ACS Medicinal Chemistry Letters
March 14, 2024
Robert B. Kargbo
Recent innovations in neurostimulation, psychedelic therapy, and brain function optimization are advancing personalized brain therapy. Methods for altering brain states include AI-driven non-invasive neurostimulation. The therapeutic potential of N-isopropyl tryptamines and tryptamine derivatives is examined, alongside psilocybin and psilocin crystalline forms for mental health and central nervous system disorders. These diverse approaches are compared for their mechanistic insights and therapeutic implications, contributing to neuroscience and mental health.
ACS Medicinal Chemistry Letters
January 9, 2025
Robert B. Kargbo
Artificial intelligence can enhance psychedelic research by helping to personalize treatment, predict therapeutic outcomes, and untangle the complex biological and environmental factors involved. AI models offer new understanding of long-term efficacy, how to optimize set and setting, and alternative treatment approaches, moving psychedelic therapy toward personalized medicine.